Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
Status:
Withdrawn
Trial end date:
2023-08-10
Target enrollment:
Participant gender:
Summary
This is aPhase II Study of Leronlimab (PRO 140) in combination with Regorafenib in Patients
with CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)